Anne Le Touze

Dr. Anne Le Touze


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2020
Verified
Book Chapter
Open access
PDF file
ATAnne Le Touze
Anne Le Touze
Physiological healing process is not much different in children, but the resulting scar is very rich in collagen and very dense. Therefore, when dealing with children, it is necessary to be aware of these particularities and to “guide” the scaring process to avoid disgracious and disabling scars.

27 August 2020 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
CHCoralie Hermetet
Coralie Hermetet
ELEmeline LAURENT
Emeline LAURENT
YAYasmine El Allali
Yasmine El Allali
CGChristophe Gaborit
Christophe Gaborit
AUAnnie Urvois-Grange
Annie Urvois-Grange
LGLeslie Grammatico-Guillon
Leslie Grammatico-Guillon

17 August 2016 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LGLaetitia Goffinet
Laetitia Goffinet
AOAbderrahim Oussalah
Abderrahim Oussalah
RGRosa-Maria Guéant-Rodriguez
Rosa-Maria Guéant-Rodriguez
CCCéline Chery
Céline Chery
MBMirta Basha
Mirta Basha
JGJean-Louis Guéant
Jean-Louis Guéant
Background Orofacial cleft (OFC) is the most prevalent craniofacial birth defect. Genes involved in one-carbon, folate and vitamin B12 metabolisms have been associated with OFC but no study performed a concomitant assessment on genes involved in these three pathways. Objective We looked for potential genetic variants associated with OFC using an exhaustive gene panel of one-carbon metabolism. Methods We performed a case–control discovery study on children with OFC (236 cases, 145 controls) and their related mothers (186 cases, 127 controls). We performed a replication study on the top significant genetic variant in an independent group from Belgium (248 cases, 225 controls). Results In the discovery study on ‘mothers’, the CBS locus reached array-wide significance (p=9.13×10−6; Bonferroni p=4.77×10−3; OR 0.47 (0.33 to 0.66)) among the 519 haplotypes tested for their association with OFC risk. Within the CBS haplotype block (rs2124459, rs6586282, rs4920037, rs234705, rs234709), the rs2124459 was the most significantly associated with a reduced risk of OFC (p=1.77×10−4; Bonferroni p=2.00×10−2; OR 0.53 (0.38 to 0.74), minor allele). The rs2124459 was associated with a reduced risk of cleft palate (CP) (p=6.78×10−5; Bonferroni p=7.80×10−3; OR 0.40 (0.25 to 0.63)). In the ‘children’ group, the rs2124459 was associated with a reduced risk of CP (p=0.02; OR 0.61 (0.40 to 0.93), minor allele). The association between rs2124459 and reduced risk of CP was replicated in an independent children population from Belgium (p=0.02; OR 0.64 (0.44 to 0.93), minor allele). Conclusions The CBS rs2124459 was associated with a reduced risk of CP in both French and Belgian populations. These results highlight the prominent involvement of the vitamin B6-dependent transsulfuration pathway of homocysteine in OFC risk and the interest for evaluating vitamin B6 status in further population studies.

18 March 2019 in Archives de Pédiatrie
Verified
Journal Article
Closed access
PMP. Meignan
P. Meignan
WLW. Lakhal
W. Lakhal
ABAurelien BINET
Aurelien BINET
ATAnne Le Touze
Anne Le Touze
BCB. De Courtivron
B. De Courtivron
TOT. Odent
T. Odent

5 November 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
AMAnnabel Maruani
Annabel Maruani
AMAnne-Guillemette Moineau
Anne-Guillemette Moineau
OBOlivia Boccara
Olivia Boccara
JMJuliette Mazereeuw-Hautier
Juliette Mazereeuw-Hautier
SLSophie Leducq
Sophie Leducq
JRJérôme Rollin
Jérôme Rollin
Dear Editor, Slow-flow vascular malformations (VMs), particularly venous VMs, might get complicated by intramalformative thrombosis linked to localized intravascular coagulopathy (LIC).1–3 Several studies have shown the effectiveness of sirolimus on slow-flow VMs but its effect on coagulation has been poorly studied.3 Moreover, vascular endothelial growth factor (VEGF) A and C are known for their proangiogenic and lymphangiogenic activities, respectively, and sirolimus may reduce their levels.4 In this study, we investigated blood levels of VEGF-A and -C, tissue factor (TF) and coagulation markers in children with slow-flow VMs before and after sirolimus treatment. The protocol was approved by the institutional review board of the University Hospital Centre of Tours (#2015-R18) and received authorization from Agence Nationale de Sécurité du Médicament et des produits de santé. The data may be shared on reasonable request (submitted to dpo@chu-tours.fr).

30 June 2010 in Archives de Pédiatrie
Verified
Journal Article
Closed access
ATAnne Le Touze
Anne Le Touze